Pharmacological Management of Stage 2 Hypertension

Definition

Treatment Algorithm

Core Principle

First-Line Drug Classes (Without Compelling Indications)

Beta-blockers are NOT recommended as first-line agents for uncomplicated hypertension - they are inferior to the above four classes, especially for stroke prevention. They retain a role when there are compelling indications (heart failure, post-MI, angina, AF rate control). - Harrison's Principles of Internal Medicine, 22nd Ed.

Initial Combination Strategy

• Diuretic (chlorthalidone/indapamide) + CCB (amlodipine), or
• Diuretic + ACEI/ARB, or
• CCB + ACEI/ARB

Hemodynamic Effects of Key Drug Classes

Special Populations - Compelling Indications

• Harrison's Principles of Internal Medicine, 22nd Ed.; Goodman & Gilman's, Fuster and Hurst's The Heart

Stepwise Escalation

Step 1 (Stage 2): Nonpharmacologic therapy + TWO drugs (diuretic or CCB + ACEI/ARB)
                                     ↓ [Reassess in 1 month]
Step 2 (not at goal):        TRIPLE therapy → diuretic + CCB + ACEI or ARB
                                     ↓
Step 3 (resistant HTN):    Add MRA (e.g., spironolactone 25-50 mg) ± vasodilators
                                     ↓
Step 4 (refractory):        Add alpha-blocker, centrally acting agent, or refer to specialist

Drug-Specific Considerations

Diuretics

• Chlorthalidone and indapamide are preferred over HCTZ - longer half-life provides 24-hour BP coverage including nocturnal control, and most landmark U.S. trials used chlorthalidone.
• Watch for: hypokalemia, hyperuricemia, mild hyperglycemia, hyponatremia.
• Potassium-sparing agents (amiloride, triamterene) can be added to counter diuretic-induced hypokalemia. - Harrison's Principles of Internal Medicine, 22nd Ed.

ACEI

• Preferred in: diabetic nephropathy, CKD with proteinuria, post-MI, systolic HF.
• Main adverse effect: dry cough (5-20%, class effect due to bradykinin accumulation) - switch to ARB if this occurs.
• Contraindicated in: pregnancy, bilateral renal artery stenosis, angioedema history, hyperkalemia.

ARB

• Same indications as ACEI; use when ACEI-induced cough occurs.
• Side effects are rare; no angioedema or cough.
• Do not combine ACEI + ARB (dual RAS blockade increases risk of renal impairment and hyperkalemia). - Goodman & Gilman's The Pharmacological Basis of Therapeutics

CCB (dihydropyridines - amlodipine)

• Especially useful in: Black adults, elderly, isolated systolic HTN, angina, Raynaud's.
• Adverse effects: peripheral edema (especially at higher doses), flushing, reflex tachycardia.
• No metabolic adverse effects.

Non-DHP CCB (diltiazem, verapamil)

• Use for rate control in AF, angina.
• Avoid in HFrEF (negative inotropy).
• Do not combine with beta-blockers (risk of bradycardia/AV block).

Nonpharmacologic Therapy (Mandatory Adjunct)

• DASH diet: reduces SBP by ~5 mmHg
• Sodium restriction (< 2.4 g/day): ~5 mmHg reduction
• Weight loss: ~1 mmHg per kg lost
• Aerobic exercise (30 min/day, 5 days/week): ~4-5 mmHg reduction
• Alcohol moderation: ≤2 drinks/day men, ≤1 drink/day women
• Smoking cessation (no direct BP effect but major CVD risk reduction)

Follow-Up

• Reassess in 1 month after initiating therapy for Stage 2 HTN.
• If BP goal is met, reassess every 3-6 months.
• If goal is not met, assess adherence, then intensify therapy.
• Home BP monitoring (HBPM) - 3 morning and 3 evening readings on 3 days prior to clinic visits - is recommended to guide management.

• ACC/AHA 2017 Hypertension Guideline - Whelton et al.
• Harrison's Principles of Internal Medicine, 22nd Ed. (2025), Chapter 288
• Goodman & Gilman's The Pharmacological Basis of Therapeutics, Chapter 32

Note from recent literature: A 2024 meta-analysis (PMID 38532223) confirms fixed-dose combination therapy for cardiovascular prevention is effective; and a 2024 systematic review (PMID 38616212) highlights emerging drug strategies (renal denervation, novel mineralocorticoid antagonists) for resistant hypertension. A 2025 systematic review (PMID 41036884) reinforces that atenolol is inferior to other first-line agents and should not be used as first-line monotherapy for uncomplicated hypertension.

Amlodipine - Uses and Adverse Effects

Drug Profile

• Morgan and Mikhail's Clinical Anesthesiology, 7th Ed.

Mechanism of Action

• Vascular smooth muscle relaxation → decreased peripheral vascular resistance → BP reduction
• Coronary artery vasodilation → increased oxygen supply to myocardium
• Minimal effect on cardiac conduction (AV node, SA node) - this distinguishes it from non-DHP CCBs like verapamil/diltiazem

Therapeutic Uses

1. Hypertension (Primary Use)

• A first-line antihypertensive - among the most prescribed drugs worldwide
• Particularly effective in:
  • Black patients (good efficacy as monotherapy; RAS blockers are less effective alone in this population)
  • Elderly patients with isolated systolic hypertension
  • Patients with concurrent angina
  • Patients with Raynaud's phenomenon (vasodilatory benefit)
• Used in Stage 2 HTN combination therapy: typically paired with an ACEI/ARB (CCB + ACEI/ARB is a preferred first-step combination)
• Long-acting DHP CCBs like amlodipine are among the first-choice agents in HTN per current guidelines - Goodman & Gilman's The Pharmacological Basis of Therapeutics

2. Angina Pectoris

• Reduces myocardial O2 demand by decreasing afterload (peripheral vasodilation)
• Reduces cardiac workload

• Highly effective - relaxes coronary artery spasm directly
• The vasodilatory effect of amlodipine is particularly useful in variant angina caused by spontaneous coronary spasm - Lippincott Illustrated Reviews: Pharmacology

3. Other Uses

• Coronary artery disease (CAD) - reduces anginal episodes
• Hypertensive urgency (oral, slower onset than IV agents but safe for subacute use)
• Hypertension in CKD - no dose adjustment needed; no nephrotoxicity
• Hypertension + Heart Failure with Preserved EF (HFpEF) - DHP CCBs are safe (unlike non-DHP CCBs)

Note: Short-acting dihydropyridines (sublingual nifedipine) should be avoided in CAD - evidence of increased mortality post-MI and increased risk of acute MI in hypertensive patients due to excessive reflex sympathetic activation. - Lippincott Illustrated Reviews: Pharmacology

Adverse Effects

Common (Vasodilation-Related)

Less Common

Rare but Notable

• Exacerbation of heart failure - amlodipine is relatively safe in HF compared to other CCBs, but high doses may worsen HF in some patients. The PRAISE trials found amlodipine did not increase mortality in HFrEF, unlike non-DHP CCBs.
• Drug interactions via CYP3A4 - amlodipine is a CYP3A4 substrate; levels may increase with CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, grapefruit juice) and decrease with inducers (e.g., rifampin) - Goodman & Gilman's The Pharmacological Basis of Therapeutics

Key Pharmacological Comparison: DHP vs. Non-DHP CCBs

• Lippincott Illustrated Reviews: Pharmacology; Morgan and Mikhail's Clinical Anesthesiology, 7th Ed.

Contraindications and Cautions

Amlodipine is safe in CKD - no dose adjustment required based on renal function. It does not cause hyperkalemia or worsen renal function.

Key Clinical Pearls

• Ankle edema from amlodipine can be reduced by combining it with an ACEI/ARB (venodilation counters the arteriolar-predominant vasodilation), rather than automatically stopping the drug or adding a diuretic.
• Because of its 30-50 hour half-life, amlodipine provides stable 24-hour BP coverage, making it excellent for once-daily dosing and reducing the risk of BP surges between doses.
• It is metabolically neutral - no effects on glucose, lipids, uric acid, or electrolytes. This distinguishes it from thiazide diuretics and beta-blockers.
• Unlike beta-blockers, amlodipine does not mask hypoglycemia symptoms and is safe in diabetics.